Pancreatic Cancer Research

ResearcherUniversity Medical Center Hamburg-EppendorfActive in the last 2 years

Faik Güntac Uzunoglu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-6890-4829; OpenAlex author ID A5074676972. Sources: OpenAlex.

Their work

Papers
34 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
131
Papers, trials and grants by year

2014: 2 papers · 2015: none · 2016: none · 2017: none · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: 4 papers · 2022: 4 papers · 2023: 10 papers · 2024: 2 papers · 2025: 6 papers · 2026: 4 papers

Papers 34

  1. Concordance between GPT-4 and a multidisciplinary tumor board in pancreatic cancer: A prospective pilot study. Co-author DOI 10.1007/s00423-026-04242-9↗
  2. International survey on neoadjuvant treatments in anatomically resectable pancreatic adenocarcinoma (INSPIRA): a real-life snapshot. Co-author DOI 10.1016/j.suronc.2026.102580↗
  3. Impact of preoperative radiotherapy on the risk of postpancreatectomy haemorrhage and major morbidity after resection of pancreatic adenocarcinoma including ar… Co-author DOI 10.1093/bjsopen/zrag058↗
  4. Neoadjuvant therapy for left-sided resectable pancreatic ductal adenocarcinoma: evidence-based shift or premature extrapolation? Co-author DOI 10.21037/hbsn-2025-587↗
  5. Routine Imaging or Symptomatic Follow-Up After Resection of Pancreatic Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2024.5024↗
  6. Polymorphisms within autophagy-related genes as susceptibility biomarkers for pancreatic cancer: A meta-analysis of three large European cohorts and functional… Co-author DOI 10.1002/ijc.35196↗
  7. Patient-derived tumor organoids highlight the potential of precision medicine in managing pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.35443↗
  8. Author Correction: Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer. Co-author DOI 10.1038/s41586-025-08979-z↗
  9. A pleiotropy scan to discover new susceptibility loci for pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/mutage/geae012↗
  10. Identification and characterization of tumor and stromal derived liquid biopsy analytes in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13046-024-03262-x↗
  11. Potential association between PSCA rs2976395 functional variant and pancreatic cancer risk. Co-author DOI 10.1002/ijc.35046↗
  12. Polymorphisms in transcription factor binding sites and enhancer regions and pancreatic ductal adenocarcinoma risk. Co-author DOI 10.1186/s40246-024-00576-x↗
  13. Association between a polymorphic variant in the CDKN2B-AS1/ANRIL gene and pancreatic cancer risk. Co-author DOI 10.1002/ijc.34383↗
  14. The PANcreatic Disease ReseArch (PANDoRA) consortium: Ten years' experience of association studies to understand the genetic architecture of pancreatic cancer. Co-author DOI 10.1016/j.critrevonc.2023.104020↗
  15. Genetic and non-genetic risk factors for early-onset pancreatic cancer. Co-author DOI 10.1016/j.dld.2023.02.023↗
  16. Determination of "borderline resectable" pancreatic cancer - A global assessment of 30 shades of grey. Co-author DOI 10.1016/j.hpb.2023.07.883↗
  17. Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer. Co-author DOI 10.1038/s41586-023-05728-y↗
  18. A scan of all coding region variants of the human genome, identifies 13q12.2-rs9579139 and 15q24.1-rs2277598 as novel risk loci for pancreatic ductal adenocarc… Co-author DOI 10.1093/carcin/bgad056↗
  19. Peripheral and Portal Venous KRAS ctDNA Detection as Independent Prognostic Markers of Early Tumor Recurrence in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1093/clinchem/hvac214↗
  20. Polymorphic variants involved in methylation regulation: a strategy to discover risk loci for pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/jmg-2022-108910↗
  21. Exploring the Neandertal legacy of pancreatic ductal adenocarcinoma risk in Eurasians. Co-author DOI 10.1186/s40659-023-00457-y↗
  22. Effects of Exercise Training on Patient-Specific Outcomes in Pancreatic Cancer Patients: A Scoping Review. Co-author DOI 10.3390/cancers15245899↗
  23. Tumor-Stroma Interaction in PDAC as a New Approach for Liquid Biopsy and its Potential Clinical Implications. Co-author DOI 10.3389/fcell.2022.918795↗
  24. Circulating Cancer Associated Macrophage-like Cells as a Potential New Prognostic Marker in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/biomedicines10112955↗
  25. Characterization of RARRES1 Expression on Circulating Tumor Cells as Unfavorable Prognostic Marker in Resected Pancreatic Ductal Adenocarcinoma Patients. Co-author DOI 10.3390/cancers14184405↗
  26. Biomarkers in Liquid Biopsies for Prediction of Early Liver Metastases in Pancreatic Cancer. Co-author DOI 10.3390/cancers14194605↗
  27. Genetic Polymorphisms Involved in Mitochondrial Metabolism and Pancreatic Cancer Risk. Co-author DOI 10.1158/1055-9965.epi-21-0353↗
  28. Association of Genetic Variants Affecting microRNAs and Pancreatic Cancer Risk. Co-author DOI 10.3389/fgene.2021.693933↗
  29. Identification of Recessively Inherited Genetic Variants Potentially Linked to Pancreatic Cancer Risk. Co-author DOI 10.3389/fonc.2021.771312↗
  30. Evaluation of the Hamburg-Glasgow Classification in Pancreatic Cancer: Preoperative Staging by Combining Disseminated Tumor Load and Systemic Inflammation. Co-author DOI 10.3390/cancers13235942↗
  31. Biperiden and mepazine effectively inhibit MALT1 activity and tumor growth in pancreatic cancer. Co-author DOI 10.1002/ijc.32567↗
  32. Evaluation of the MDACC clinical classification system for pancreatic cancer patients in an European multicenter cohort. Co-author DOI 10.1016/j.ejso.2018.12.012↗
  33. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). First author DOI 10.1016/j.surg.2014.02.001↗
  34. The multifunctional growth factor midkine promotes proliferation and migration in pancreatic cancer. Co-author DOI 10.1158/1541-7786.mcr-13-0467↗

Closest collaborators

The 25 strongest of 131 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Marianne Sinn · 10 shared papers, 2022–2026 · strength 1.77
  2. Jakob Robert Izbicki · 13 shared papers, 2014–2025 · strength 1.57
  3. Thilo Hackert · 6 shared papers, 2023–2026 · strength 1.27
  4. Harriet Wikman · 6 shared papers, 2022–2025 · strength 0.99
  5. Christine Nitschke · 6 shared papers, 2022–2025 · strength 0.99
  6. Cenap Güngör · 5 shared papers, 2014–2025 · strength 0.55
  7. Leonie Konczalla · 4 shared papers, 2020–2025 · strength 0.51
  8. John P. Neoptolemos · 3 shared papers, 2014–2026 · strength 0.46
  9. Thilo Welsch · 2 shared papers, 2026 · strength 0.45
  10. Joseph Tintelnot · 3 shared papers, 2023–2025 · strength 0.43
  11. Julian Götze · 2 shared papers, 2022–2025 · strength 0.37
  12. Thomas P. Hank · 1 shared paper, 2026 · strength 0.32
  13. Martin Loos · 1 shared paper, 2026 · strength 0.32
  14. Christoph Springfeld · 1 shared paper, 2026 · strength 0.32
  15. Christoph W. Michalski · 1 shared paper, 2026 · strength 0.32
  16. Casper H.J. van Eijck · 2 shared papers, 2023–2026 · strength 0.29
  17. Danmei Zhang · 2 shared papers, 2023–2025 · strength 0.29
  18. Nicola Gagliani · 2 shared papers, 2023–2025 · strength 0.29
  19. Marija Trajkovic‐Arsic · 2 shared papers, 2023–2025 · strength 0.29
  20. Jens Thomas Siveke · 2 shared papers, 2023–2025 · strength 0.29
  21. Alec C. Kimmelman · 2 shared papers, 2023–2025 · strength 0.29
  22. Stefan Hubert Boeck · 2 shared papers, 2023–2025 · strength 0.29
  23. Anna Nießen · 1 shared paper, 2026 · strength 0.27
  24. Fiete Gehrisch · 1 shared paper, 2026 · strength 0.27
  25. Maximilian Bockhorn · 4 shared papers, 2014–2020 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.